CVE:LXG

LexaGene Competitors

C$0.67
-0.06 (-8.22 %)
(As of 04/19/2021 03:58 PM ET)
Add
Compare
Today's Range
C$0.65
Now: C$0.67
C$0.73
50-Day Range
C$0.75
MA: C$0.96
C$1.13
52-Week Range
C$0.58
Now: C$0.67
C$1.54
Volume234,564 shs
Average Volume456,544 shs
Market CapitalizationC$76.62 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

LexaGene (CVE:LXG) Vs. AKU, SQD, SVA, GEN, LMD, and VPT

Should you be buying LXG stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to LexaGene, including Akumin (AKU), SQI Diagnostics (SQD), Sernova (SVA), GeneNews (GEN), LED Medical Diagnostics (LMD), and VentriPoint Diagnostics (VPT).

LexaGene (CVE:LXG) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for LexaGene and Akumin, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LexaGene0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, suggesting a potential upside of 8.97%. Given Akumin's higher probable upside, analysts clearly believe Akumin is more favorable than LexaGene.

Profitability

This table compares LexaGene and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LexaGeneN/AN/AN/A
AkuminN/AN/AN/A

Valuation & Earnings

This table compares LexaGene and Akumin's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneN/AN/AN/AC($0.12)-5.63
AkuminC$246.08 million1.10C$-25,194,260.00C($0.36)-10.71

LexaGene has higher earnings, but lower revenue than Akumin. Akumin is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Summary

Akumin beats LexaGene on 3 of the 5 factors compared between the two stocks.

SQI Diagnostics (CVE:SQD) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares SQI Diagnostics and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQI DiagnosticsN/AN/AN/A
LexaGeneN/AN/AN/A

Valuation & Earnings

This table compares SQI Diagnostics and LexaGene's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQI DiagnosticsC$977,000.00101.13C$-12,264,984.00C($0.04)-8.06
LexaGeneN/AN/AN/AC($0.12)-5.63

LexaGene has lower revenue, but higher earnings than SQI Diagnostics. SQI Diagnostics is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for SQI Diagnostics and LexaGene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQI Diagnostics0000N/A
LexaGene0000N/A

Summary

SQI Diagnostics beats LexaGene on 2 of the 3 factors compared between the two stocks.

Sernova (CVE:SVA) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Profitability

This table compares Sernova and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SernovaN/AN/AN/A
LexaGeneN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Sernova and LexaGene, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sernova0000N/A
LexaGene0000N/A

Earnings and Valuation

This table compares Sernova and LexaGene's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/AN/AC($0.03)-55.56
LexaGeneN/AN/AN/AC($0.12)-5.63

Sernova is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

GeneNews (TSE:GEN) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares GeneNews and LexaGene's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneNewsC$234,592.00108.68C$-11,557,484.00C($0.07)-2.21
LexaGeneN/AN/AN/AC($0.12)-5.63

LexaGene has lower revenue, but higher earnings than GeneNews. LexaGene is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for GeneNews and LexaGene, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GeneNews0000N/A
LexaGene0000N/A

Profitability

This table compares GeneNews and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GeneNewsN/AN/AN/A
LexaGeneN/AN/AN/A

Summary

GeneNews beats LexaGene on 3 of the 3 factors compared between the two stocks.

LED Medical Diagnostics (CVE:LMD) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Profitability

This table compares LED Medical Diagnostics and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LED Medical DiagnosticsN/AN/AN/A
LexaGeneN/AN/AN/A

Valuation & Earnings

This table compares LED Medical Diagnostics and LexaGene's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96 million1.04C$-1,512,615.00C($0.04)-10.26
LexaGeneN/AN/AN/AC($0.12)-5.63

LexaGene has lower revenue, but higher earnings than LED Medical Diagnostics. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for LED Medical Diagnostics and LexaGene, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LED Medical Diagnostics0000N/A
LexaGene0000N/A

Summary

LED Medical Diagnostics beats LexaGene on 2 of the 3 factors compared between the two stocks.

LexaGene (CVE:LXG) and VentriPoint Diagnostics (CVE:VPT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Profitability

This table compares LexaGene and VentriPoint Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LexaGeneN/AN/AN/A
VentriPoint DiagnosticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for LexaGene and VentriPoint Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LexaGene0000N/A
VentriPoint Diagnostics0000N/A

Valuation and Earnings

This table compares LexaGene and VentriPoint Diagnostics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneN/AN/AN/AC($0.12)-5.63
VentriPoint DiagnosticsC$37,517.002,000.65C$-4,128,201.00C($0.03)-18.18

LexaGene has higher earnings, but lower revenue than VentriPoint Diagnostics. VentriPoint Diagnostics is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Summary

VentriPoint Diagnostics beats LexaGene on 2 of the 3 factors compared between the two stocks.


LexaGene Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKU
Akumin
0.7$3.90-0.3%C$270.63 millionC$246.08 million-10.71
SQD
SQI Diagnostics
0.9$0.29-5.2%C$52.59 millionC$977,000.00-8.06Gap Down
SVA
Sernova
0.5$1.50-0.0%C$31.35 millionN/A-55.56
GEN
GeneNews
0.5$0.15-6.7%C$24.65 millionC$234,592.00-2.21
LMD
LED Medical Diagnostics
0.4$0.40-100.0%C$15.51 millionC$14.96 million-10.26Gap Down
VPT
VentriPoint Diagnostics
0.6$0.60-1.7%C$5.58 millionC$37,517.00-18.18Gap Up
IDL
Imaging Dynamics
0.4$0.08-13.3%C$4.13 millionC$378,253.00-3.95Gap Down
DXD
3D Signatures
0.5$0.04-100.0%C$2.66 millionN/A-0.91Gap Down
MBI
Med Biogene
0.5$0.05-22.2%C$795,000.00N/A-7.50Gap Up
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.